LBB-66
Pharmaceutical compound
From Wikipedia, the free encyclopedia
LBB-66, also known as lysergic acid dibutylamide or as N,N-dibutyllysergamide, is a serotonin receptor modulator of the lysergamide family related to lysergic acid diethylamide (LSD; LSD-25).[1][2][3] It is the derivative of LSD in which the N,N-diethyl groups have been replaced with N,N-dibutyl groups.[1][2][3]
- None
| Clinical data | |
|---|---|
| Other names | LBB66; LA-dibutylamide; Lysergic acid dibutylamide; N,N-Dibutyllysergamide; N,N-Dibutyl-6-methyl-9,10-didehydroergoline-8β-carboxamide |
| Drug class | Serotonin receptor modulator |
| ATC code |
|
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C24H33N3O |
| Molar mass | 379.548 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
The drug has about 31% or around one-third of the antiserotonergic activity of LSD in the isolated rat uterus in vitro.[1][4][5][6] In contrast to other assessed lysergamides, it has been said to bind practically irreversibly in this context.[5] Unlike LSD, LBB-66 is said to be devoid of psychedelic effects in humans, with a hallucinogenic potency relative to LSD of 0% stated, but the tested doses not given.[1]
LBB-66 was first described in the scientific literature by Albert Hofmann and colleagues by 1955.[7][8][9][10]